Submit to Healthcare Review for Healthcare Propose a Special Issue

Journal Browser

► Journal Browser

Cancer in Human Health and Healthcare

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Healthcare (ISSN 2227-9032).

Deadline for manuscript submissions: closed (21 January 2022) | Viewed by 41872

Share This Special Issue

Special Issue Editors

Dr. Nur Mohammad Hassan

E-Mail Website
Guest Editor

School of Dentistry and Health Sciences, Charles Sturt University, NSW, 2800, Australia
Interests: oral health; systemic disease; molecular biology; oral pathology; cancer-related genetics; head and neck squamous cell carcinoma

Dr. Rahena Akhter

E-Mail Website
Guest Editor

School of Dentistry, Faculty of Medicine and Health, The University of Sydney, Camperdown 2006, Australia
Interests: caries risk assessment; caries management system; minimal intervention dentistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will facilitate the publication of high-quality original research and review articles pertaining to the genetic, genomic, and molecular aspects of cancer, its relation with systemic disease, and technical advances that facilitate progress in this field.

The aim of this Special Issue is to provide a platform for researchers, physicians, surgeons, and academicians around the globe to promote, share, and discuss various new issues and developments in different fields of oral cancer, especially the correlation of genetic changes with pathology and clinical presentation, and the molecular genetics of cancer predisposition. To reach a basic science and clinical multidisciplinary audience, we welcome original full-length articles, reviews, and editorials on the epidemiology, prevention, clinical features, diagnosis, treatment, and management of patients with neoplasms in the head and neck as well as its relation with systemic diseases.

Dr. Nur Mohammad Hassan
Dr. Rahena Akhter
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

oral health, systemic disease
molecular biology
oral pathology
cancer-related genetics
head and neck squamous cell carcinoma

Published Papers (14 papers)

Download All Papers

Research

Jump to: Review

12 pages, 1373 KiB

Open AccessArticle

Cost-Effectiveness of Prostate Cancer Detection in Biopsy-Naïve Men: Ultrasound Shear Wave Elastography vs. Multiparametric Diagnostic Magnetic Resonance Imaging

by Mehdi Shiva, Cheng Wei, Hassan Molana and Ghulam Nabi

Healthcare 2022, 10(2), 254; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare10020254 - 28 Jan 2022

Cited by 2 | Viewed by 3118

Abstract

This exploratory study investigates the cost-effectiveness of ultrasound shear wave elastography (SWE) imaging in comparison to pre-biopsy multiparametric magnetic resonance imaging (mpMRI) in men with suspected prostate cancer. This research is motivated by the early evidence of the good performance of SWE in distinguishing cancerous from benign prostate tissues. We used a decision analysis model representing the care-pathways of men referred with a high prostate specific antigen (PSA) and/or abnormal digital rectal examination (DRE) in a UK setting from the payer’s perspective with results reported in 2016 GBP. We then appraised the cost-effectiveness of a novel approach based on SWE compared to the more conventional and widely practiced mpMRI-based approaches using data reported in the literature. Deterministic and probabilistic sensitivity analyses were used to address uncertainty regarding the parameter values utilised. Our exploratory results implied that SWE approach yielded an additional quality-adjusted life year (QALY) at the cost of GBP 10,048 compared to the standard mpMRI-based approach in the UK. This is lower than the official willingness to pay threshold of GBP 20,000 (the UK healthcare system guidelines) and is therefore a suitable replacement for the current practice. Sensitivity analyses confirmed the robustness of our results. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

9 pages, 404 KiB

Open AccessArticle

The Role of Music Therapy for Children Undergoing Cancer Treatment in Singapore

by Kayla Carissa Wong, Beron W. Z. Tan, Jasper W. K. Tong and Mei Yoke Chan

Healthcare 2021, 9(12), 1761; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9121761 - 20 Dec 2021

Cited by 5 | Viewed by 4961

Abstract

The aim of this study was to explore the benefits of music therapy (MT) for children with cancer over the course of their treatment in an acute paediatric hospital setting in Singapore. Twenty-five children undergoing cancer treatment received MT sessions as part of a multidisciplinary team rehabilitation intervention from March 2017 to January 2020. A total of 37 individualised goals were developed by the music therapist for the cohort. Goals were scored via the Goal Attainment Scale at 3-month intervals up to 1 year. Descriptive statistics and correlation analysis were used to evaluate the findings. The rate of goal achievement was 89.2% over 180 MT sessions (M = 7.20, SD = 6.45). Children diagnosed with brain tumours had the highest frequency of MT sessions (M = 9.11, SD = 7.79). Most of the goals targeted the regulation of mood and morale through music. There was a positive correlation found between goals and sessions (r_s = 0.56, p = 0.004). Age of the children was not correlated with the number of sessions received (r_s= −0.19, p = 0.354). MT has been found to be an accessible and effective intervention in addressing functional and emotional goals for children across all ages who are undergoing cancer treatment. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

10 pages, 276 KiB

Open AccessArticle

Cancer as a Chronic Illness in Colombia: A Normative Consensus Approach to Improving Healthcare Services for those Living with and beyond Cancer and Its Treatment

by Cindy V. Mendieta, Maria Elizabeth Gómez-Neva, Laura Victoria Rivera-Amézquita, Esther de Vries, Martha Lucía Arévalo-Reyez, Santiago Rodriguez-Ariza, Carlos J. Castro E and Sara Faithfull

Healthcare 2021, 9(12), 1655; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9121655 - 29 Nov 2021

Cited by 5 | Viewed by 2827

Abstract

Cancer survivorship care in Colombia is of increasing importance. International survivorship initiatives and studies show that continuing symptoms, psychological distress, and late effects impact the quality of life for survivors. Priorities for quality survivorship according to Colombian patients and clinicians are unknown. We undertook a nominal consensus approach with 24 participants using virtual meeting technology to identify the priorities for cancer survivorship. We applied an iterative approach conducted over eight weeks with five workshops and one patient focus group followed by a priority setting survey. The consensus group established six main themes, which were subsequently evaluated by experts: (i) symptoms and secondary effects of cancer; (ii) care coordination to increase patient access and integration of cancer care; (iii) psychosocial support after cancer treatment; (iv) mapping information resources and available support services for long-term cancer care; (v) identifying socioeconomic and regional inequalities in cancer survival to improve care and outcomes; and (vi) health promotion and encouraging lifestyle change. The order of priorities differed between clinicians and patients: patients mentioned psychosocial support as the number one priority, and clinicians prioritized symptoms and surveillance for cancer recurrence. Developing survivorship care needs consideration of both views, including barriers such as access to services and socioeconomic disparities. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

20 pages, 3947 KiB

Open AccessArticle

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

by Emily Jiggens, Maria Mortoglou, Guy H. Grant and Pinar Uysal-Onganer

Healthcare 2021, 9(11), 1478; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9111478 - 30 Oct 2021

Cited by 2 | Viewed by 2363

Abstract

Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

10 pages, 1107 KiB

Open AccessArticle

Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience

by Kiyoka Sawada, Kentaro Nakayama, Kohei Nakamura, Yuki Yoshimura, Sultana Razia, Masako Ishikawa, Hitomi Yamashita, Tomoka Ishibashi, Seiya Sato and Satoru Kyo

Healthcare 2021, 9(10), 1395; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9101395 - 19 Oct 2021

Viewed by 1628

Abstract

Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examine the efficacy and clinical feasibility of genotype-matched therapy. Target sequencing was performed in 20 cases of gynecological cancers (cervical cancer, 6; endometrial cancer, 6; and ovarian cancer, 6). Both actionable and druggable genes were identified in 95% (19/20) of the cases. Among them, seven patients (35%) received genotype-matched therapy, which was effective in three patients. Of the three patients, one patient with a PTEN mutation received everolimus, another patient with a TSC2 mutation received everolimus and letrozole, and the patient with a BRIP1 mutation received olaparib. Subsequently, disease control in these three patients lasted for more than half a year. However, all patients relapsed between 9 and 13 months after the initiation of genotype-matched therapy. In this study, the response rate of genotype-matched therapy was 43% (3/7), which may have contributed to improved prognoses. Therefore, genotype-matched therapies may help patients with refractory gynecological cancers achieve better outcomes. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

12 pages, 1004 KiB

Open AccessArticle

Association of Health-Related Quality of Life with Overall Survival in Older Americans with Kidney Cancer: A Population-Based Cohort Study

by Naleen Raj Bhandari, Mohamed H. Kamel, Erin E. Kent, Carrie McAdam-Marx, Songthip T. Ounpraseuth, J. Mick Tilford and Nalin Payakachat

Healthcare 2021, 9(10), 1344; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9101344 - 10 Oct 2021

Cited by 1 | Viewed by 1974

Abstract

Background: Our purpose was to evaluate associations between health-related quality of life (HRQoL) and overall survival (OS) in a population-based sample of kidney cancer (KC) patients in the US. Methods: We analyzed a longitudinal cohort (n = 188) using the Surveillance, Epidemiology, and End Results (SEER) database linked with the Medicare Health Outcomes Survey (MHOS; 1998–2014). We included KC patients aged ≥65 years, with a completed MHOS during baseline (pre-diagnosis) and another during follow-up (post-diagnosis). We reported HRQoL as physical component summary (PCS) and mental component summary (MCS) scores and OS as number of months from diagnosis to death/end-of-follow-up. Findings were reported as adjusted hazard ratios (aHRs (95% CI)) from Cox Proportional Hazard models. Results: The aHRs associated with a 3-point lower average (baseline and follow-up) or a 3-point within-patient decline (change) in HRQoL with OS were: (a) baseline: PCS (1.08 (1.01–1.16)) and MCS (1.09 (1.01–1.18)); (b) follow-up: PCS (1.21 (1.12–1.31)) and MCS (1.11 (1.04–1.19)); and (c) change: PCS (1.10 (1.02–1.18)) and MCS (1.02 (0.95–1.10)). Conclusions: Reduced HRQoL was associated with worse OS and this association was strongest for post-diagnosis PCS, followed by change in PCS and pre-diagnosis PCS. Findings highlight the prognostic value of HRQoL on OS, emphasize the importance of monitoring PCS in evaluating KC prognosis, and contribute additional evidence to support the implementation of patient-reported outcomes in clinical settings. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

11 pages, 580 KiB

Open AccessArticle

Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer

by Kai-Ling Huang, Yu-Ling Liu, Ya-Ying Hsu and Wen-Ling Kuo

Healthcare 2021, 9(9), 1203; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9091203 - 13 Sep 2021

Cited by 4 | Viewed by 1780

Abstract

Bilateral breast cancer is a strong predictor of BRCA 1/2 mutation and hence one criterion indicated for hereditary genetic testing. The purpose of this study is to assess the characteristics of synchronous bilateral breast cancer (SBBC) and its association with personal and familial cancer traits. Patients diagnosed with SBBC in our institute between 1992 and 2018 were retrospectively reviewed, and the information of clinicopathological features, personal and family cancer history were analyzed. Of the 307 SBBCs enrolled, the growing case number generally aligned with the regional breast cancer incidence after the era of population-based mammography screening. SBBC patients had similar cancer stages but worse survival outcomes than those in the standard scenario. A total of 42.0% had mixed pathological diagnoses, and 22.8% had discordant immunohistochemistry (IHC) subtypes from both sides, which contributed to treatment challenges. The correlation of SBBC with hereditary breast and ovarian cancer (HBOC) syndrome was strongly implied, as 20.7% of our SBBC patients with known familial cancer histories had HOBC-related familial cancers (breast, ovarian, or prostate cancers). These findings highlight the need for genetic counseling and germline mutation testing in patients with SBBC. Early PARP inhibitor treatment should also be considered in high-risk cases for outcome improvement. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

9 pages, 2407 KiB

Open AccessArticle

Effect of Ranitidine Intake on the Risk of Gastric Cancer Development

by SunMoon Kim, Suehyun Lee, JeeYoung Hong, Inseok Ko, Jong-Yeup Kim and Dong-Kyu Kim

Healthcare 2021, 9(8), 1071; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9081071 - 20 Aug 2021

Cited by 6 | Viewed by 2855

Abstract

Gastric cancer is one of the most prevalent cancers globally, with high mortality, particularly in East Asia. Certain ranitidine products contain potentially carcinogenic N-nitrosodimethylamine. We investigated the potential association between gastric cancer risk and ranitidine intake using a nationwide cohort, extracted from the Korean National Health Insurance Service. In this longitudinal study, we employed a 1:1 propensity score matching according to sociodemographic factors. A total of 40,887 subjects were enrolled, of which 906 developed gastric cancer during the follow-up period. We investigated gastric cancer events during the follow-up period using the survival analysis, log-rank test, and Cox proportional hazards regression models to estimate incidence, survival rate, and hazard ratio. The incidence of gastric cancer was 67,422; 67,470; and 67,444 person-years in the control, other histamine-2 blockers, and ranitidine groups, respectively. Because the adjusted hazard ratio of gastric cancer was 0.98 and 1.01 in the other histamine-2 blockers and ranitidine groups, respectively, we could not calculate the likelihood of gastric cancer development in the ranitidine group. Ranitidine intake did not significantly increase the incidence of gastric cancer. Therefore, the relative risk of gastric cancer may be low in patients taking ranitidine products in South Korea. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

6 pages, 178 KiB

Open AccessArticle

Extended Venous Resections for Borderline Resectable Pancreatic Head Adenocarcinoma—A Retrospective Studies of Nine Cases

by Nicolae Bacalbasa, Irina Balescu, Mihai Dimitriu, Cristian Balalau, Florentina Furtunescu, Florentina Gherghiceanu, Daniel Radavoi, Camelia Diaconu, Ovidiu Stiru, Cornel Savu, Vladislav Brasoveanu, Claudia Stoica and Ioan Cordos

Healthcare 2021, 9(8), 978; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9080978 - 31 Jul 2021

Viewed by 1480

Abstract

Background: pancreatic cancer is one of the most lethal malignancies and a leading cause of cancer-related death worldwide. The only chance to improve the long-term outcomes of patients with pancreatic cancer is surgery with radical intent. Methods: in the present paper, we aim to describe a case series of 9 patients submitted to radical surgery for borderline resectable pancreatic cancer. Results: in all cases, negative resection margins were achieved. The types of venous resection consisted of tangential portal vein resection in four cases, circumferential portal vein resection with direct reanastomosis in one case and circumferential resection with graft placement in another four cases; postoperatively, one patient developed a vascular surgery-related complication consisting of graft thrombosis and thus necessitated prolonged anticoagulant therapy. Conclusions: extended venous resections can be a safe and efficient way to maximize the benefits of radical surgery in locally advanced, borderline resectable pancreatic cancer. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

10 pages, 1104 KiB

Open AccessArticle

Image Registration of ¹⁸F-FDG PET/CT Using the MotionFree Algorithm and CT Protocols through Phantom Study and Clinical Evaluation

by Deok-Hwan Kim, Eun-Hye Yoo, Ui-Seong Hong, Jun-Hyeok Kim, Young-Heon Ko, Seung-Cheol Moon, Miju Cheon and Jang Yoo

Healthcare 2021, 9(6), 669; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9060669 - 04 Jun 2021

Cited by 2 | Viewed by 2077

Abstract

We evaluated the benefits of the MotionFree algorithm through phantom and patient studies. The various sizes of phantom and vacuum vials were linked to RPM moving with or without MotionFree application. A total of 600 patients were divided into six groups by breathing protocols and CT scanning time. Breathing protocols were applied as follows: (a) patients who underwent scanning without any breathing instructions; (b) patients who were instructed to hold their breath after expiration during CT scan; and (c) patients who were instructed to breathe naturally. The length of PET/CT misregistration was measured and we defined the misregistration when it exceeded 10 mm. In the phantom tests, the images produced by the MotionFree algorithm were observed to have excellent agreement with static images. There were significant differences in PET/CT misregistration according to CT scanning time and each breathing protocol. When applying the type (c) protocol, decreasing the CT scanning time significantly reduced the frequency and length of misregistrations (p < 0.05). The MotionFree application is able to correct respiratory motion artifacts and to accurately quantify lesions. The shorter time of CT scan can reduce the frequency, and the natural breathing protocol also decreases the lengths of misregistrations. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

11 pages, 406 KiB

Open AccessArticle

Evaluation of Blood Stool Test Utilization for Colorectal Cancer Screening in Georgia, USA

by Benjamin E. Ansa, Nicollette Lewis, Zachary Hoffman, Biplab Datta and J. Aaron Johnson

Healthcare 2021, 9(5), 569; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9050569 - 12 May 2021

Cited by 4 | Viewed by 2368

Abstract

Colorectal cancer (CRC) is the third most prevalent cancer and the second most common cause of cancer-related deaths in the United States (USA). Early screening has been demonstrated to improve clinical outcomes for CRC. Assessing patterns in CRC screening utilization is important for guiding policy and implementing programs for CRC prevention and control. This study examines the trends and sociodemographic factors associated with blood stool test utilization (BSTU) for CRC screening in Georgia, USA. The Behavioral Risk Factor Surveillance System (BRFSS) data were analyzed for Average Annual Percent Change (AAPC) in BSTU between 1997 and 2014 among adults aged 50+ who have had a blood stool test within the past two years, and logistic regression analysis of the 2016 data was performed to identify the associated sociodemographic factors. In Georgia, an overall decrease was observed in BSTU, from 27.8% in 1997 to 16.1% in 2014 (AAPC = −2.6, p = 0.023). The decrease in BSTU was less pronounced in Georgia than nationally (from 26.1% in 1997 to 12.8% in 2014 (AAPC = −4.5, p < 0.001)). BSTU was significantly associated with black race/ethnicity (Black vs. White (aOR = 1.43, p = 0.015)), older age (≥70 vs. 50–59 (aOR = 1.62, p = 0.006)), having insurance coverage (no vs. yes (aOR = 0.37 p = 0.005)), and lower income (≥USD 50,000 vs. <USD 25,000 (aOR = 0.70 p = 0.050)). These findings reveal a decrease over time in BSTU in Georgia, with existing differences between sociodemographic groups. Understanding these patterns helps in directing tailored programs for promoting CRC screening, especially among disadvantaged populations. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

Review

Jump to: Research

11 pages, 1804 KiB

Open AccessReview

Comprehensive Studies of Different Cancer Diseases among Less-Developed Countries

by Mohammed M. Rahman, Firoz A. D. M. Opo and Abdullah M. Asiri

Healthcare 2022, 10(3), 424; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare10030424 - 24 Feb 2022

Cited by 5 | Viewed by 5745

Abstract

Recently, the rate of cancer deaths in less-developed countries such as Bangladesh has significantly increased day by day, making it a major health issue. The most predominant types of cancers among the populations of less-developed countries (especially Bangladesh) are lung, throat, colon, gastric, ovarian, breast, and skin cancers. The mortality rate is increasing for both males and females. The main common factors are smoking, use of tobacco leaves, bacterial or viral infection, hereditary disorders, food adulterations, and environmental factors, which are highly responsible for the development of carcinoma in the young to adult population in this region. Raising consciousness among people regarding early diagnosis, decreasing the use of chemicals such as formalin for food preservation, and reducing environmental pollution such as arsenic as well as air pollution might help to reduce the number of deaths. Education and public campaigns can also reduce the intensity of cancer occurrence. Breast, esophagus, and cervical cancer are common diseases in less-developed countries such as Bangladesh. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

13 pages, 2895 KiB

Open AccessReview

Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis

by Daniel Sur, Cristina Lungulescu, Irina-Ioana Puscariu, Simona Ruxandra Volovat, Madalina Preda, Elena Adriana Mateianu and Cristian Virgil Lungulescu

Healthcare 2022, 10(1), 75; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare10010075 - 31 Dec 2021

Cited by 5 | Viewed by 1970

Abstract

Patients with microsatellite-instability-high (MSI-H) or mismatched repair-deficient colorectal cancer (CRC) appear to be responsive to checkpoint inhibitors. This study aimed to assess research trends in CRC immunotherapy. Publication patterns of articles covering immunotherapies in CRC in the Web of Science Core Collection database were retrospectively examined using VOS viewer software (version 1.6.16) prior to 25 May 2021. Ultimately, 3977 records were identified that were published between 1975 and 2021, which received a total of 128,681 citations (an average of 32.36 citations per item), with a noticeable rise in 2014. The majority of articles were published in the US (35.8%), China (17.7%), and Germany (9.4%). Publications mainly originated from the Institut National de la Santé Et De La Recherche Medicale Inserm, followed by the University of Texas System and Harvard University; however, Johns Hopkins University received the most citations (18,666 for 69 publications). The Journal of Clinical Oncology issued the most publications (n = 146), while the most referenced item (7724 citations) was published in the New England Journal of Medicine in 2012. The most common keywords were associated with tumors (expression and microsatellite instability) or immune system components (t-cells/dendritic cells). The findings demonstrate the scientific community’s interest in the MSI-H subtype of colorectal tumors and how immunotherapy may be employed more successfully to treat metastatic CRC. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

12 pages, 3845 KiB

Open AccessReview

Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)

by Nikola A. Ivica and Colin M. Young

Healthcare 2021, 9(8), 1062; https://0-doi-org.brum.beds.ac.uk/10.3390/healthcare9081062 - 19 Aug 2021

Cited by 22 | Viewed by 5336

Abstract

Chimeric antigen receptor and T-cell receptor (CAR-T/TCR-T) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other types of cancer. In this paper, we look at all available FDA CAR-T/TCR-T clinical trials for the treatment of cancer, and analyze them with respect to different disease tissues, targeted antigens, products, and originator locations. We found that 627 of 1007 registered are currently active and of those 273 (44%) originated in China and 280 (45%) in the US. Our analysis suggests that the rapid increase in the number of clinical trials is driven by the development of different CAR-T products that use a similar therapeutic approach. We coin the term bioparallels to describe such products. Our results suggest that one feature of the CAR-T/TCR-T industry may be a robust response to success and failure of competitor products. Full article

(This article belongs to the Special Issue Cancer in Human Health and Healthcare)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cancer in Human Health and Healthcare

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (14 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI